In recent years, poultry producers have faced increasing challenges from infectious diseases
that reduce productivity and flock health. Newcastle Disease (ND) and Avian Influenza (AI), particularly Low Pathogenic Avian Influenza (LPAI) H9N2, are major concerns, especially in regions like the Middle East, Asia and Africa due to continuous virus circulation, high stocking density, and environmental stress.
Although LPAI H9N2 often causes mild or subclinical signs, it has strong immunosuppressive effects that increase susceptibility to secondary infections, especially ND. Field observations show ND and AI often occur simultaneously. Separate vaccinations increase labor, chicken stress and operational complexity, making simplified and efficient vaccination strategies a critical priority.
To address these challenges, Medivac ND G7-AI H9N2 (Figure 1) has been developed as a practical, dual-protection solution. This inactivated vaccine combines ND virus genotype VII with LPAI H9N2. By delivering protection against two major respiratory threats in a single injection, it supports stronger immune responses while reducing vaccination workload. A controlled Specific Pathogen Free (SPF) chickens trial showed that Medivac ND G7-AI H9N2 induces strong, reliable immunity against both ND Genotype VII and LPAI H9N2 (Figure 2). Birds vaccinated at 28 days achieved HI titers well above standard benchmarks just 3 weeks later—HI 29.3 for ND GVII and HI 210.7 for H9N2—confirming robust, genotype-matched dual protection from a single shot. Medivac ND G7-AI H9N2 offers flexible administration for all poultry sectors.
For broilers, a 0.2 mL subcutaneous dose form the first week provides early protection and simplifies vaccination schedule. In layers and breeders, the vaccine ensures stability from the pullet phase into production. Trials in pullets vaccinated at 4 days and 8 weeks resulted in antibody titers above standard levels, ensuring optimal immunity prior to the laying period (Figure 3).
Trials in laying period chicken vaccinated at 15 and 36 weeks demonstrated protective antibody titers throughout the production period (Figure 4) – ensuring sustained immunity against ND Genotype VII and LPAI H9N2 from rearing to the end of the laying cycle. While vaccination plays a vital role, optimal disease control also depends on strict biosecurity and good farm management practices. Backed by Medion’s commitment to innovation and quality, Medivac ND G7-AI H9N2 supports sustainable poultry production under challenging field conditions.
For more information, visit www.medionfarma.co.id
